ERCC1 Measurements in Clinical Oncology

Publisher Website
Google Scholar
Abstract
Clinical oncology has struggled for decades with the predicament of the toxicity of chemotherapy for the treatment of malignant disease. For example, cisplatin and its analogues, carboplatin and oxaliplatin, are commonly used anticancer agents, but they are particularly toxic. Moreover, some patients benefit substantially from treatment with these drugs, whereas others suffer the toxic effects of the drugs without obtaining real benefit. The use of molecular markers to help identify who may benefit and who may not is one of the most exciting new areas of study in oncology.The randomized International Adjuvant Lung Cancer Trial (IALT) found a modest . . .